database (p<0.01). There was no significant difference in overall survival (OS) between patients with and without DRG SNPs (log-rank p¼0.46). There was no significant association between the most commonly identified SNP rs11342077 and OS among UC patients with DRG SNPs (log-rank p¼0.39). Overall, the presence of DRG SNPs in our cohort (33/53, 62.3%) occurred at a significantly higher frequency compared to the ExAC database (0.56%, Chisquare p<0.01).
INTRODUCTION AND OBJECTIVES:
Introduction and Objectives: Human urothelial cancers can be classified into luminal or basal subtypes based on RNA and protein expression that have distinct clinical behaviors and responsiveness to chemotherapy. Therefore, it is essential to classify experimental animal models of bladder cancer based on molecular subtypes. In this study, we characterized N-methyl-N-nitrosourea (MNU)-induced bladder tumors in rats and ex vivo-cultured spheroids derived from them to determine their similarities to the luminal and basal subtypes observed in human cancers.
METHODS: Female Fisher 344 rats at age of 7 weeks received 4 intravesical doses of 1.5mg/kg MNU. By week 8, the MNU bladders displayed evidence of dysplasia and by week 16 small animal ultrasounds revealed papillary tumors with associated CIS, high grade non-invasive disease, or invasion into the lamina propria. In order to assess the subtype memberships of mature invasive tumors, rats were sacrificed at 30 weeks. Bladder tumors were evaluated by H&E staining and immunohistochemistry using antibodies against basal marker CK14 and luminal CK20. Ex-vivo culture of tumor cells was carried out using a spheroidal culture method. Partially digested tumor fragments were cultured in StemProâ medium. Viability of ex-vivo cultured cells was evaluated by Ki67 immunohistochemical staining and growth assay under microscope. Cultured cells were also tested by immnohistochestry using antibodies of CK14 and CK20.
RESULTS: By about 30 weeks after exposure to MNU, rats developed 5-10-mm, protruding tumors in their bladders. Immunohistochemistry revealed enrichment of CK14-stained cells in CIS lesions and invasive tumors compared to normal urothelium, while the number of CK20-stained cells declined. Papillary tumors had a mixed staining pattern with both CK14 and CK20 positive staining. Partially digested fragments of tumors formed clear spheroids 24 hours after digestion. Immunohistochemistry revealed CK14-positive cells comprised 88% of spheroids and CK20-positive cells less than 5%.
CONCLUSIONS: The results of the present study demonstrate a pre-clinical model of urothelial cancer associated with progression of papillary non-muscle invasive bladder tumors with associated CIS to invasive cancers. CIS, invasive tumors, and ex-vivo cultured spheroids had the appearance of a basal subtype membership, while papillary tumors from the same model had staining patterns consistent with the urobasal/luminal tumor subtype. METHODS: Tumor specimens, including primary bladder tumors and lymph node metastases, were collected from 29 bladder cancer patients having standard of care tumor resection, who also had consented to an IRB-approved protocol for TIL generation. The tissue was minced into fragments, placed in individual wells of a 24-well plate, and propagated in high dose IL-2 for four weeks. TIL were considered expanded if they propagated to fill ¼2 wells. The remaining tumor material was digested into a single cell suspension and frozen. TIL were phenotyped by flow cytometry and assessed for autologous tumor reactivity through co-culture with tumor digest and IFN-gamma ELISA.
RESULTS: Twenty-seven of 29 tumors were harvested from radical cystectomy patients. Urothelial cell bladder tumors were cultured from 23 patients, of whom 19 (83%) demonstrated TIL expansion. Among these were 9/12 with preceding chemotherapy and 10/11 which had been chemotherapy naive. Expanded TIL were predominantly CD3þ (median 63%, range 10-87%) with a median of 30% CD8þ T cells (range 5-70%). Eight of 15 tested samples (53%) contained TIL that secreted IFN-gamma in response to autologous tumor. Microbial contamination was observed in six specimens. All lymphatic (5/5 samples) tissue collected demonstrated TIL expansion.
CONCLUSIONS: The study establishes the practical first step towards an autologous TIL therapy process for therapeutic testing in patients with bladder cancer. Human bladder cancer tissue can be used to expand tumor-specific TIL in vitro. TIL were also able to be expanded from patients that received chemotherapy prior to tumor resection. Future efforts will explore the ability to further expand bladder TIL cultures to clinically meaningful numbers to develop novel ACT strategies for patients with this diagnosis.
